CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Surface Oncology SURF, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that data from the Phase 1 study of SRF231, a fully human, high-affinity anti-CD47 antibody, will be presented at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, to be held virtually May 29-31.
A summary is provided below; the full poster will be placed on Surface Oncology's website following the presentation.
Presentation Type: e-poster (Abstract: 3064 / Poster: 128)
Title: Results of a first-in-human Phase 1 study of SRF231, a fully human, high-affinity anti-CD47 antibody
Lead Author: Amita Patnaik
Session: Developmental Therapeutics - Immunotherapy
In 2018, Surface Oncology deprioritized the SRF231 clinical program and is concluding its Phase 1 study.
About Surface Oncology:
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (via targeting CD112R) or depleting regulatory T cells (via targeting CCR8). Surface's novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contacts:
Investors
Matt Lane
matt@gilmartinir.com
617-901-7698
Media
Tom Donovan
tom@tenbridgecommunications.com
857-559-3397
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.